Loading patent…
AssigneeApotech Research and Development Ltd.
InventorsJürg Tschopp, Pascal Schneider, Nils Holler
Estimating the term…
The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. The oligomers are characterized in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a biological function, in particular with a ligand function for antibodies, for soluble or membranous signal molecules, for receptors or an antibody, or an antibody segment, and component B contains a protein or a protein segment which dimerizes or oligomerizes the dimer, trimer, quatromer or pentamer of the recombinant fusion protein, without the action of third-party molecules. The invention also relates to the use of dimers or oligomers of this type for producing a medicament, to the fusion proteins which cluster in dimers or oligomers and to their DNA sequence and expression vectors or host cells comprising this DNA sequence.
A recombinant fusion protein having at least one component A and at least one component B, wherein component A comprises an extracellular segment of FasL protein capable of binding to the Fas receptor and component B comprises a protein segment of ACRP30 comprising the collagen-like segment of ACRP30 without the globular head domain of ACRP30, which oligomerizes the recombinant fusion protein without the effect of third molecules, and wherein said recombinant fusion protein comprises a linker sequence between component A and component B.
A recombinant fusion protein having at least one component A and at least one component B, wherein component A comprises an extracellular segment of FasL protein capable of binding to the Fas receptor and component B comprises a protein segment of ACRP30 comprising the collagen-like segment of ACRP30 without the globular head domain of ACRP30, which oligomerizes the recombinant fusion protein without the effect of third molecules, wherein component B comprises amino acids 18 to 111 of mACRP30, or amino acids 18 to 108 of hACRP30.
A recombinant fusion protein having at least one component A and at least one component B, wherein component A comprises an extracellular segment of FasL protein capable of binding to the Fas receptor and component B comprises a protein segment of ACRP30 comprising the collagen-like segment of ACRP30 without the globular head domain of ACRP30, which oligomerizes the recombinant fusion protein without the effect of third molecules, wherein component A is amino acids 139-261 of hFasL.
A recombinant fusion protein having at least one component A and a least one component B, wherein component A comprises amino acids 139-261 of hFasL and component B comprises amino acids 18-111 of mACRP30 or amino acids 18 to 108 of hACRP30.
Dependencies are inferred from the claim text.